MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Gilead Sciences Inc.

Closed

SectorHealthcare

111.99 0.86

Overview

Share price change

24h

Current

Min

110.44

Max

111.99

Key metrics

By Trading Economics

Income

530M

1.8B

Sales

29M

7.6B

P/E

Sector Avg

294.868

63.778

EPS

1.9

Dividend yield

2.82

Profit margin

23.557

Employees

17,600

EBITDA

-655M

3.1B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+3.64% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.82%

2.39%

Next Earnings

24 kwi 2025

Next Dividend date

26 cze 2025

Next Ex Dividend date

13 cze 2025

Market Stats

By TradingEconomics

Market Cap

18B

140B

Previous open

111.13

Previous close

111.99

News Sentiment

By Acuity

46%

54%

169 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Gilead Sciences Inc. Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 lut 2025, 21:17 UTC

Earnings

Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised

19 gru 2024, 15:25 UTC

Major Market Movers

Assembly Biosciences Shares Rise 19% After Gilead Investment, Funding

19 gru 2024, 13:38 UTC

Major Market Movers

Assembly Biosciences Gets $30.1 Million Equity Investment, Funding From Gilead

6 lis 2024, 22:25 UTC

Earnings

Gilead Sciences Post Higher 3Q Revenue, Raises Fiscal Year Guidance

19 mar 2025, 14:50 UTC

Top News

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

28 lut 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11 lut 2025, 22:13 UTC

Market Talk
Earnings

Gilead's HIV Segment Buoying Product Sales Amid Covid Losses -- Market Talk

11 lut 2025, 21:06 UTC

Earnings

Gilead Beats Earnings Estimates on Strong HIV Sales -- Barrons.com

11 lut 2025, 21:02 UTC

Earnings

Gilead Sciences Planning for Potential Launch of Lenacapavir for HIV PrEP in Summer 2025>GILD

11 lut 2025, 21:02 UTC

Earnings

Gilead Sciences Sees 2025 EPS $5.95-EPS $6.35 >GILD

11 lut 2025, 21:02 UTC

Earnings

Gilead Sciences Raises Dividend to 79c Vs. 77c >GILD

11 lut 2025, 21:02 UTC

Earnings

Gilead Sciences Sees 2025 Product Sales Excluding Veklury $26.8B - $27.2B>GILD

11 lut 2025, 21:02 UTC

Earnings

Gilead Sciences Raises Dividend 2.6%>GILD

11 lut 2025, 21:02 UTC

Earnings

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

11 lut 2025, 21:02 UTC

Earnings

Gilead Sciences Sees 2205 Veklury Sales $1.4B>GILD

11 lut 2025, 21:02 UTC

Earnings

Gilead Sciences Sees 2025 Sales $28.2B-$28.6B >GILD

11 lut 2025, 21:02 UTC

Earnings

Gilead Sciences 4Q >GILD

11 lut 2025, 21:02 UTC

Earnings

Gilead Sciences 4Q HCV Products Sales >GILD

11 lut 2025, 21:02 UTC

Earnings

Gilead Sciences 4Q Rev Up on HIV, Oncology, Liver Disease; Partially Offset by lower sales of Veklury (Remdesivir) >GILD

11 lut 2025, 21:02 UTC

Earnings

Gilead Sciences 4Q Adj EPS $1.90 >GILD

11 lut 2025, 21:02 UTC

Earnings

Gilead Sciences 4Q Rev $7.57B >GILD

11 lut 2025, 21:02 UTC

Earnings

Gilead Sciences 4Q EPS $1.42 >GILD

11 lut 2025, 21:02 UTC

Earnings

Gilead Sciences 4Q EPS $1.42 >GILD

11 lut 2025, 21:02 UTC

Earnings

Gilead Sciences 4Q Net $1.78B >GILD

11 lut 2025, 21:02 UTC

Earnings

Gilead Sciences 4Q Rev $7.6B >GILD

11 lut 2025, 21:02 UTC

Earnings

Gilead Sciences 4Q Adj EPS $1.90 >GILD

10 sty 2025, 10:30 UTC

Top News

Trump Says World Is Free-Riding on U.S. Health Spending. He Has a Point. -- WSJ

29 gru 2024, 08:00 UTC

Acquisitions, Mergers, Takeovers

Gilead Buys $20.1 Million of Assembly Biosciences Stock -- Barrons.com

19 gru 2024, 13:23 UTC

Major Market Movers

Assembly Biosciences Gets $30.1M Equity Investment, Funding From Gilead

7 lis 2024, 16:23 UTC

Earnings

Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise -- IBD

Peer Comparison

Price change

Gilead Sciences Inc. Forecast

Price Target

By TipRanks

3.64% upside

12 Months Forecast

Average 115.33 USD  3.64%

High 140 USD

Low 90 USD

Based on 23 Wall Street analysts offering 12 month price targets forGilead Sciences Inc. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

23 ratings

17

Buy

6

Hold

0

Sell

Technical Score

By Trading Central

109.84 / 112.2Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Neutral Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

169 / 386 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.